OSP: What are some of the key differences in patient recruitment with DCTs and hybrid trials, compared to traditional, onsite trials? Recent data showed the Black population accounted for 21% of deaths from COVID-19, yet only 3% of Black individuals participated in clinical trials related to COVID-19 vaccines. The lack of diverse representation in clinical trials was laid bare throughout the fast-tracked COVID-19 research. The pandemic also reinforced the importance of diversity in trials. With the news sharing details on vaccine development, efficacy, and approvals, the importance and clinical value of trials was demonstrated to the public. The pandemic forced the industry’s hand, making new technologies and methodologies necessary for trial success.ĬOVID-19 pushed vaccine trials into daily media coverage, bringing awareness of clinical research to an all-time high. COVID-19 had a huge impact on clinical research, pausing active trials and putting trials in the pipeline on hold. IC: Buzz around DCTs and hybrid designs has been around for years however, it took the in-person restrictions brought about by COVID-19 to accelerate their adoptions. OSP: How did the arrival of COVID-19 change the game?

While there has been a trend toward innovation, such as new technologies used to target patients and an emphasis on novel patient accommodations, the industry has seen low adoption rates. When we educate and engage the 96% of the population that have never participated, a healthy portion of people will be interested in clinical research if the process is simple. Only 4% of the US population has ever participated in a clinical trial so there's a huge opportunity to expand the reach and impact of trial participation. Lack of diversity: The clinical research industry acknowledges a lack of diversity in clinical trial participants and seeks to rectify the problem.Lack of trial awareness: One of the biggest challenges to finding participants for clinical trials is that most people, certainly before the pandemic, didn't even know that clinical trials exist or what they are, for that matter.IC: Unfortunately, patient recruitment has not changed enough in recent years to move the needle on some of the most important problems facing recruitment: OSP: Could you please talk about some of the ways in which patient recruitment has evolved in recent years? What are some of the new technologies, practices, philosophies, etc., we’ve seen emerge?

The rise of decentralized clinical trials (DCTs) has transformed the research landscape. Tabletting, coating & ancillary equipmentĭecentralized trials Outsourcing-Pharma connected with SubjectWell CEO Ivor Clarke on how patient recruitment has advanced in recent years, challenges faced in decentralized clinical trial (DCT) recruitment, and advice on how to step up recruitment efforts.Excipients, raw materials and intermediates.APIs (active pharmaceutical ingredients).

Crystal ball software